Blackout Periods

Blackout Periods, in the context of an employer-sponsored 401(k) plan, refer to specific periods during which participants are temporarily restricted from making changes to their investment allocations or accessing their retirement account. These blackout periods typically occur when significant changes are being made to the plan, such as plan conversions, mergers, or changes in plan administrators. During this time, participants are unable to make adjustments to their investment choices, including buying, selling, or reallocating their assets within the plan.

Examples:

  • Plan Restructuring: Suppose Company A decides to switch its 401(k) plan administrator due to better investment options and lower administrative costs. During the transition, a blackout period may be implemented to prevent participants from making changes to their portfolios until the new administrator takes over the plan fully.
  • Mergers and Acquisitions: In the case of a merger or acquisition involving Company B, where the acquired company's employees are integrated into the 401(k) plan of the acquiring company, a blackout period might be enforced to consolidate accounts and ensure a smooth transition for all participants.
  • Investment Option Changes: If Company C decides to replace certain investment options in their 401(k) plan with new ones to improve the plan's performance, a blackout period may be put in place to facilitate the switch without disruptions caused by participant trading activities.

During blackout periods, employees are encouraged to review their investment strategies beforehand and consider any necessary adjustments to their portfolios. It is essential for employers to provide advance notice of these blackout periods to ensure transparency and help participants plan accordingly.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.